- Home
- ACRV vs BRNS Comparison
ACRV vs BRNS Comparison
Compare ACRV & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRV | BRNS |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.4M | 55.9M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACRV | BRNS |
|---|---|---|
| Price | $1.56 | $0.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $11.67 | $4.00 |
| AVG Volume (30 Days) | ★ 602.8K | 29.8K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $568.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.05 | $0.51 |
| 52 Week High | $3.56 | $2.91 |
Technical Indicators
Market Signals| Indicator | ACRV | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 46.94 |
| Support Level | $1.49 | $0.54 |
| Resistance Level | $1.86 | $0.62 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.86 | 44.53 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.